MARKET

SYN

SYN

SYNTHETIC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4806
+0.0028
+0.59%
After Hours: 0.4643 -0.0163 -3.39% 19:46 09/17 EDT
OPEN
0.4800
PREV CLOSE
0.4778
HIGH
0.4806
LOW
0.4566
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
1.700
52 WEEK LOW
0.2610
MARKET CAP
63.46M
P/E (TTM)
-1.1013
1D
5D
1M
3M
1Y
5Y
Irritable Bowel Syndrome Drugs Market: Expected CAGR, Top Manufacturers and Consumer Analysis across the Region and Globe, Opportunities and Growth till 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/08 06:26
Irritable Bowel Syndrome Drugs Market- Up-To-Date Statistics, Development Areas And Emerging Opportunities Worldwide 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/03 13:51
Synthetic Biologics EPS in-line
Synthetic Biologics (NYSE:SYN): Q2 GAAP EPS of -$0.02 in-line. Current cash position of approximately $74.3M. "During the second quarter, we remained focused on the advancement of our portfolio of gastrointestinal
Seekingalpha · 08/05 20:39
BRIEF-Synthetic Biologics Posts Q2 Loss Per Share $0.02
reuters.com · 08/05 20:18
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET
/PRNewswire/ -- (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today provided a clinical programs upda...
PR Newswire - PRF · 08/05 20:10
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
BRIEF-Synthetic Biologics Expands Option For Exclusive License Agreement With Massachusetts General Hospital
reuters.com · 08/03 11:40
Synthetic Biologics Reports Expansion Of Option For Exclusive License Deal With Massachusetts General Hospital
Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of
Benzinga · 08/03 11:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYN. Analyze the recent business situations of SYNTHETIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYN stock price target is 1.875 with a high estimate of 2.500 and a low estimate of 1.250.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.75M
% Owned: 1.32%
Shares Outstanding: 132.04M
TypeInstitutionsShares
Increased
3
253.42K
New
2
98.10K
Decreased
6
47.38K
Sold Out
5
523.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Independent Director
John Monahan
Independent Director
Jeffrey Wolf
No Data
  • All
  • Financials
  • Insiders
More
About SYN
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.